GlassScriptPhysician profile
Jeremy Larson
NPI 1932551801
$2,418.84
in general payments reported to CMS, 2019-2025
20 companies · $702 in 2025
The $702 reported for 2025 was more than what 76% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $641 · 2020: $141 · 2022: $366 · 2023: $204 · 2024: $365 · 2025: $702.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,271.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,270.67 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $721.86 | 2019-2025 | Spravato, Invega Sustenna |
| Otsuka America Pharmaceutical, INC. | $306.62 | 2019-2025 | Abilify Asimtufii, Abilify Maintena |
| Braeburn INC. | $189.64 | 2023-2025 | Brixadi |
| Teva Pharmaceuticals USA, INC. | $180.54 | 2019-2025 | Austedo Xr |
| Sunovion Pharmaceuticals INC. | $156.54 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $148.48 | 2024-2025 | Cobenfy |
| Abbvie INC. | $131.12 | 2022-2025 | |
| Indivior INC. | $116.67 | 2019-2025 | Sublocade |
| Neurocrine Biosciences, INC. | $116.18 | 2019-2025 | |
| Supernus Pharmaceuticals, INC. | $65.97 | 2025 | Qelbree |
| Alkermes, INC. | $57.62 | 2019 | |
| Lundbeck LLC | $37.62 | 2019 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $33.61 | 2019 | |
| Tempus Ai, INC | $30.44 | 2024 | |
| Allergan, INC. | $29.99 | 2019 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $27.74 | 2020-2022 | |
| Janssen Scientific Affairs, LLC | $23.57 | 2023 | Spravato |
| Takeda Pharmaceuticals U.S.A., INC. | $17.31 | 2020 | |
| Globus Medical, INC. | $16.44 | 2022 | |
| Vanda Pharmaceuticals INC. | $10.88 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeremy Larson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.